| # | Title | Journal | Year | Citations |
|---|
| 1 | Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria | Annals of Neurology | 2011 | 8,001 |
| 2 | The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic | Nature Reviews Gastroenterology and Hepatology | 2014 | 5,773 |
| 3 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria | Lancet Neurology, The | 2018 | 4,605 |
| 4 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 | Intensive Care Medicine | 2017 | 4,590 |
| 5 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Lancet Oncology, The | 2010 | 1,915 |
| 6 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study | Lancet, The | 2019 | 1,804 |
| 7 | An integrated catalog of reference genes in the human gut microbiome | Nature Biotechnology | 2014 | 1,664 |
| 8 | Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 | Intensive Care Medicine | 2021 | 1,503 |
| 9 | Cervical cancer | Lancet, The | 2019 | 1,367 |
| 10 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,261 |
| 11 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Annals of Oncology | 2012 | 1,233 |
| 12 | Gastroduodenal Disorders | Gastroenterology | 2016 | 1,088 |
| 13 | ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors | Neuroendocrinology | 2016 | 1,074 |
| 14 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort | Lancet, The | 2010 | 1,061 |
| 15 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 | Nature Reviews Cancer | 2009 | 993 |
| 16 | The gut microbiota in IBD | Nature Reviews Gastroenterology and Hepatology | 2012 | 984 |
| 17 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2017 | 975 |
| 18 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study | Lancet, The | 2011 | 949 |
| 19 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 | Critical Care Medicine | 2021 | 927 |
| 20 | Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study | Gastroenterology | 2021 | 913 |
| 21 | Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes | Nature Biotechnology | 2014 | 909 |
| 22 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | Nature Medicine | 2018 | 900 |
| 23 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Annals of Oncology | 2013 | 895 |
| 24 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study | Lancet Oncology, The | 2013 | 849 |
| 25 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology | 2019 | 811 |
| 26 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types | Journal of Clinical Oncology | 2002 | 799 |
| 27 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial | Lancet, The | 2019 | 778 |
| 28 | The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy: Fig. 1. | Clinical Cancer Research | 2006 | 776 |
| 29 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 773 |
| 30 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization | Nature Medicine | 2002 | 729 |
| 31 | NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations | Cancer Research | 2008 | 726 |
| 32 | Development of PI3K inhibitors: lessons learned from early clinical trials | Nature Reviews Clinical Oncology | 2013 | 694 |
| 33 | Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial | Lancet, The | 2021 | 689 |
| 34 | Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2012 | 647 |
| 35 | COVID-19 pandemic: perspectives on an unfolding crisis | British Journal of Surgery | 2020 | 647 |
| 36 | Actively personalized vaccination trial for newly diagnosed glioblastoma | Nature | 2019 | 637 |
| 37 | First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement | Cancer Discovery | 2013 | 618 |
| 38 | The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer | Nature Genetics | 2009 | 616 |
| 39 | Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study | Lancet Oncology, The | 2014 | 611 |
| 40 | The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care# | International Journal of Gynecology and Obstetrics | 2015 | 608 |
| 41 | Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma | Nature Communications | 2015 | 605 |
| 42 | Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy | Journal of Clinical Oncology | 2010 | 593 |
| 43 | Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2020 | 591 |
| 44 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer | Journal of Clinical Oncology | 2009 | 582 |
| 45 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Nature | 2018 | 572 |
| 46 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer | JAMA Oncology | 2019 | 557 |
| 47 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer | JAMA Oncology | 2017 | 555 |
| 48 | Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology | 2008 | 519 |
| 49 | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study | Lancet Oncology, The | 2020 | 503 |
| 50 | Multimodality Imaging of Diseases of the Thoracic Aorta in Adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging | Journal of the American Society of Echocardiography | 2015 | 500 |
